Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Science 2019 05;364(6439):485-491

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Tumors with mismatch repair deficiency (MMR-d) are characterized by sequence alterations in microsatellites and can accumulate thousands of mutations. This high mutational burden renders tumors immunogenic and sensitive to programmed cell death-1 (PD-1) immune checkpoint inhibitors. Yet, despite their tumor immunogenicity, patients with MMR-deficient tumors experience highly variable responses, and roughly half are refractory to treatment. We present experimental and clinical evidence showing that the degree of microsatellite instability (MSI) and resultant mutational load, in part, underlies the variable response to PD-1 blockade immunotherapy in MMR-d human and mouse tumors. The extent of response is particularly associated with the accumulation of insertion-deletion (indel) mutational load. This study provides a rationale for the genome-wide characterization of MSI intensity and mutational load to better profile responses to anti-PD-1 immunotherapy across MMR-deficient human cancers.

Download full-text PDF

Source
http://www.sciencemag.org/lookup/doi/10.1126/science.aau0447
Publisher Site
http://dx.doi.org/10.1126/science.aau0447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685207PMC
May 2019
71 Reads
31.477 Impact Factor

Publication Analysis

Top Keywords

mutational load
12
mismatch repair
8
anti-pd-1 immunotherapy
8
tumors mismatch
8
repair deficiency
8
tumors
5
variable response
4
showing degree
4
evidence showing
4
clinical evidence
4
experimental clinical
4
degree microsatellite
4
instability msi
4
resultant mutational
4
underlies variable
4
treatment experimental
4
msi resultant
4
load underlies
4
microsatellite instability
4
roughly half
4

References

(Supplied by CrossRef)

Similar Publications